Aileron Therapeutics, Inc. (ALRN): Price and Financial Metrics


Aileron Therapeutics, Inc. (ALRN): $2.60

0.02 (+0.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALRN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALRN Stock Price Chart Interactive Chart >

Price chart for ALRN

ALRN Price/Volume Stats

Current price $2.60 52-week high $15.00
Prev. close $2.58 52-week low $1.79
Day low $2.59 Volume 6,300
Day high $2.80 Avg. volume 30,800
50-day MA $2.68 Dividend yield N/A
200-day MA $4.74 Market Cap 11.81M

Aileron Therapeutics, Inc. (ALRN) Company Bio


Aileron Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of therapeutics called stapled peptides, which represent the first general solution, or "scaffold" for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. The company's lead product candidate ALRN-6924 is being evaluated in multiple clinical trials. The company was founded in 2005 and is based in Cambridge, Massachusetts.


ALRN Latest News Stream


Event/Time News Detail
Loading, please wait...

ALRN Latest Social Stream


Loading social stream, please wait...

View Full ALRN Social Stream

Latest ALRN News From Around the Web

Below are the latest news stories about AILERON THERAPEUTICS INC that investors may wish to consider to help them evaluate ALRN as an investment opportunity.

What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock

Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 29, 2022

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The Nasdaq Stock Market noting that Aileron has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the company to maintain a minimum closing bid price of $1.00 p

Yahoo | November 30, 2022

Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Aileron Therapeutics, Inc. (ALRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Yahoo | November 24, 2022

Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split

Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will become effective at 5:00 p.m. ET today. Aileron’s common stock will continue to be traded on the

Yahoo | November 10, 2022

Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade

Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | November 4, 2022

Read More 'ALRN' Stories Here

ALRN Price Returns

1-mo -11.52%
3-mo -22.73%
6-mo -38.68%
1-year -70.72%
3-year -81.88%
5-year -98.35%
YTD 9.70%
2022 -78.95%
2021 -45.88%
2020 81.50%
2019 -31.79%
2018 -92.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7747 seconds.